Medibio Ltd
ASX:MEB

Watchlist Manager
Medibio Ltd Logo
Medibio Ltd
ASX:MEB
Watchlist
Price: 0.02 AUD Market Closed
Market Cap: 122m AUD
Have any thoughts about
Medibio Ltd?
Write Note

Medibio Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medibio Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Medibio Ltd
ASX:MEB
Current Portion of Long-Term Debt
AU$103.7k
CAGR 3-Years
10%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
4DMedical Ltd
ASX:4DX
Current Portion of Long-Term Debt
AU$944.6k
CAGR 3-Years
9%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
CogState Ltd
ASX:CGS
Current Portion of Long-Term Debt
$108.4k
CAGR 3-Years
-44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pro Medicus Ltd
ASX:PME
Current Portion of Long-Term Debt
AU$553k
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Medadvisor Ltd
ASX:MDR
Current Portion of Long-Term Debt
AU$12.6m
CAGR 3-Years
100%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alcidion Group Ltd
ASX:ALC
Current Portion of Long-Term Debt
AU$697k
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medibio Ltd
Glance View

Market Cap
122m AUD
Industry
Health Care

Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. The firm offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company offers a software called MEBsleep, a medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. The Company’s subsidiaries include Bioprospect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Medibio Limited USA, Invatec Health Pty Ltd and Annapanna Pty Ltd.

MEB Intrinsic Value
0.001 AUD
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Medibio Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
103.7k AUD

Based on the financial report for Jun 30, 2023, Medibio Ltd's Current Portion of Long-Term Debt amounts to 103.7k AUD.

What is Medibio Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
-3%

Over the last year, the Current Portion of Long-Term Debt growth was 56%. The average annual Current Portion of Long-Term Debt growth rates for Medibio Ltd have been 10% over the past three years , -3% over the past five years .

Back to Top